REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.97
-0.18 (-2.21%)
Sep 23, 2026, 10:23 AM EDT - Market open
REGENXBIO Revenue
REGENXBIO had revenue of $108.02M in the quarter ending June 30, 2026, with 405.73% growth. This brings the company's revenue in the last twelve months to $174.48M, up 12.00% year-over-year. In the year 2025, REGENXBIO had annual revenue of $170.44M with 104.54% growth.
Revenue (ttm)
$174.48M
Revenue Growth
+12.00%
P/S Ratio
3.08
Revenue / Employee
$470,302
Employees
371
Market Cap
526.13M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.44M | 87.11M | 104.54% |
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| Ginkgo Bioworks Holdings | 132.42M |
| Autolus Therapeutics | 117.39M |
| Assembly Biosciences | 74.85M |
| Scribe Therapeutics | 33.30M |
| Capricor Therapeutics | 11.13M |
| Ovid Therapeutics | 1.58M |
| ProKidney | 818.00K |
RGNX News
- 7 days ago - REGENXBIO Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 8 days ago - REGENXBIO Transcript: 2026 Global Healthcare Conference - Transcripts
- 15 days ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 weeks ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX) - Business Wire
- 4 weeks ago - Regenxbio price target lowered to $21 from $23 at H.C. Wainwright - TheFly
- 4 weeks ago - REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli - PRNewsWire
- 4 weeks ago - Regenxbio price target lowered to $29 from $32 at Baird - TheFly
- 4 weeks ago - Regenxbio price target lowered to $32 from $45 at Clear Street - TheFly